Overview
This is a basic overview course, intended for individuals who have limited experience in pharmacovigilance/drug safety monitoring. The focus will be on pharmacovigilance with traditional medicinal products, both investigational and marketed, intended for human use in clinical trials, in post-marketing studies, and in the healthcare setting following product launch.
Regional developments in the GCC countries will also be highlighted.
Program Committee
-
Gaby L. Danan, MD, PhD Pharmacovigilance Expert
GLD, France -
William Gregory, PhD Senior Director, Safety and Risk Management
Pfizer Inc, United States -
Bina S. Patel Director Case Management Group
GlaxoSmithKline R&D Ltd., United Kingdom -
Harri Tapani Helajarvi Former Qualified Person for Pharmacovigilance
Finland
Have an account?